Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma
Colorectal Adenocarcinoma
About this trial
This is an interventional treatment trial for Colorectal Adenocarcinoma focused on measuring capecitabine, thalidomide, colorectal cancer
Eligibility Criteria
Inclusion Criteria: Histologic proof of colorectal adenocarcinoma with radiological or cytological evidence of stage IV (metastatic) disease Measurable tumor Serum creatinine < 1.5 mg/dl Total bilirubin < 2.0 mg/dl AST < 5 x ULN ANC > 1,500/mm3 Platelets > 100,000/mm3 Hemoglobin > 9.0 gm/dl Must have received at least one prior chemotherapy regimen for metastatic colorectal cancer. At least 3 weeks must have passed since the last chemotherapy treatment 18 years of age or older ECOG performance status of less than or equal to 2 Life expectancy of greater than 12 weeks Exclusion Criteria: Prior treatment with mitomycin C or nitrosourea compounds Prior treatment with capecitabine or thalidomide Clinically apparent central nervous system metastases or carcinomatous meningitis Peripheral neuropathy of grade 2 or greater severity Myocardial infarction in the past 6 months Major surgery in the past 2 weeks Uncontrolled serious medical or psychiatric illness Pregnant or lactating women Concurrent malignancy of any site, except limited basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix. Known allergy to 5-FU
Sites / Locations
- Massachusetts General Hospital
- Dana-Farber Cancer Institute